Cipher Pharmaceuticals (TSE:CPH) Shares Cross Above Fifty Day Moving Average of $7.92

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$7.92 and traded as high as C$8.88. Cipher Pharmaceuticals shares last traded at C$8.82, with a volume of 6,227 shares.

Analysts Set New Price Targets

Separately, Citigroup lifted their price target on shares of Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the company a “buy” rating in a report on Wednesday, February 14th.

Cipher Pharmaceuticals Stock Performance

The company has a 50-day moving average of C$7.92 and a 200-day moving average of C$6.32. The firm has a market capitalization of C$211.59 million, a P/E ratio of 8.09 and a beta of 0.97. The company has a current ratio of 9.19, a quick ratio of 2.67 and a debt-to-equity ratio of 0.44.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings results on Thursday, March 14th. The company reported C$0.41 EPS for the quarter, beating analysts’ consensus estimates of C$0.15 by C$0.26. The business had revenue of C$6.70 million for the quarter, compared to analysts’ expectations of C$7.31 million. Cipher Pharmaceuticals had a net margin of 96.32% and a return on equity of 28.19%. On average, equities analysts anticipate that Cipher Pharmaceuticals Inc. will post 0.6040609 earnings per share for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.